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The study was naturalistic and thus the aim was to investigate
the impact of remission in clinical practice, without any pre-
speciﬁed protocol for the GPs to follow. Cox regression analysis
was employed to analyse what factors inﬂuence the time to
achieve remission. RESULTS: Fifty-two percent of the patients
achieved remission during the study period. During a period of
six months, remitting patients have on average three outpatient
care visits less than non-remitting patients (p = 0.0001), and 
substantially less sick-leave days: 22 days per year (p = 0.0106).
Remitting patients have a signiﬁcantly lower total cost ($3,400
during 6 months) compared with non-remitting patients (p =
0.0001). Moreover, the average EQ-5D index score was 0.24
higher in remitting patients (p = 0.0001). Severely depressed
patients have 60% lower chance of achieving remission quickly
than milder cases of depression (p = 0.002). CONCLUSIONS:
Remission has a substantial health economic impact and we have
shown both statistically signiﬁcant reductions in cost as well as
improved quality-of-life. Our results argue for the importance of
aiming for full remission in the antidepressive treatment of
depression, and hence indicating that antidepressants that
rapidly lead to full remission may be cost-effective.
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OBJECTIVE: To identify utility weights for use in cost-utility
analyses of antidepressants. METHODS: Systematic search of
MEDLINE using search terms for depression and utility/prefer-
ence weights. Utility weights by depression severity and changes
in utility by response to treatment were abstracted. Methods
used to derive utilities were cross-tabulated with the values
obtained. RESULTS: Six published studies were reviewed. Three
studies obtained utility weights using the standard gamble (SG)
method, one study used the SG and time trade-off (TTO)
methods, one study used the EQ5D TTO weights, and one study
used the quality of well being (QWB) scale weights. One of the
SG studies compared utility for those with and without depres-
sion over a 10-year time horizon (0.942 (standard deviation (SD)
0.159) versus 0.963 (SD 0.144)). The other three SG studies
compared utility for different depression severity and, depend-
ing on the whether the SG lottery was presented for temporary
or lifetime health states, estimated utilities for severe depression
were between 0.09 (SD 0.02) and 0.813 (SD 0.209) and for mild
depression were between 0.59 (SD 0.02) and 0.871 (SD 0.184).
Three of the six reviewed studies compared the gain in utility for
those who responded to treatment to those who did not. The
gain in utility for responders compared to non-responders in
these studies was: 0.053 at 1 year using the SG lifetime method;
0.180 at 4 months using the QWB weights; and 0.220 at 2
months using the EQ5D TTO weights. CONCLUSIONS: Pub-
lished estimates of utility weights for people with depression and
of the gains in utility in people recovering from depression vary
considerably depending on the method of assessment. We rec-
ommend that utility gains for antidepressant treatments be esti-
mated using SG for temporary health states along with sensitivity
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OBJECTIVES: Estimate clinical effectiveness and health out-
comes of short-term DMT that delays disability progression in
relapsing/remitting-onset deﬁnite MS (RR-onset MS). Nova
Scotia (NS) natural history data (1979–March 2004) and MS
Special Therapies Program (STP) data (July 1998–March 2004)
are analyzed. The STP provides universal full-cost coverage of
Avonex®, Betaseron®, Copaxone®, Rebif6® and Rebif12® for
RR-onset MS, as insurer of last-resort. METHODS: Extended
Disability Status Scale (EDSS) natural history (NH) increase per
year, increase avoided per DMT-year, and DMT effect size rela-
tive to NH are estimated using well-validated data (9,238 clinic
visits by 1435 persons with RR-onset MS) from the Dalhousie
MS Research Unit (DMSRU) clinic. Models estimate EDSS paths
from years-since-onset (yso) given “conventional care” or DMT.
NH data is from never-DMT-plus-ever-DMT persons or 
ever-DMT persons. Analysis is stratiﬁed by “ﬁnal” class [relaps-
ing/remitting (RRMS) or secondary progressive (SPMS)] and six
severity-yso data-cells (EDSS <= 0.5, 4 <= DSS <= 0.5; yso <= 0,
yso <= 0, yso <= 0. Health outcomes (HO), measured as EDSS-
Disability-Adjusted-Life-Years (DALYs) avoided or Health
Utility Index Mark III (HUI3)-Quality-Adjusted-Life-Years
(QALYs) gained, are estimated for DMT-treatment and post-
treatment periods. RESULTS: Estimates of annual EDSS NH
increase are much smaller for RRMS than SPMS subgroups,
larger for “ever-treated” than “never-treated” subgroups, and
increase with years-since-onset. Estimates of EDSS increase
avoided per DMT-year vary by “ﬁnal” class, NH controls, 
severity-yso data-cells and DMT-duration. Effect size relative to
NH is larger in earlier years-since-onset when disability is
“mild”, than in later years when disability is “moderate” and
more patients are SPMS. Health outcomes in DMT-periods and
post-DMT-periods increase rapidly with DMT-duration. QALY
estimates > DALY estimates. CONCLUSIONS: Short-term DMT
delays disability progression in RR-onset MS. “Real world”
DMT effectiveness estimates complement clinical trial efﬁcacy
estimates. Both contribute to models of long-term DMT effec-
tiveness, health outcomes, costs and cost-effectiveness, which
inform debates on DMT practice guidelines, treatment eligibil-
ity criteria and funding.
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OBJECTIVES: Treatment may help decrease the symptoms of
restless legs syndrome (RLS), but it is unclear how many people
with RLS receive medical care. This study sought to determine
